MicroRNA-based targeting strategies enable AAV-mediated, tissue-selective gene expression in adipose tissue and skeletal muscle of mice

Functional validation of therapeutic concepts—including understanding a target protein’s mode of action in disease-relevant tissues—is a critical component of early drug discovery research. Tissue selectivity of recombinant adeno-associated viral vectors (AAVs) is an important property for both gene therapy and the modulation of target genes in model organisms, to investigate protein function and signaling pathways in specific cell types and tissues. However, while many target tissues can be transduced efficiently by selected capsids, achieving tissue specificity remains challenging in certain contexts. In this study, we compared different microRNA (miRNA)-based strategies to transcriptionally restrict AAV expression to either adipose tissue or skeletal muscle. Our findings demonstrate that liver-specific miR122 effectively suppressed AAV9-driven liver expression, while preserving adipose tissue targeting efficiency. Similarly, AAVMYO, in combination with a muscle-specific promoter and target sites for miR208a, confined transgene expression to skeletal muscle, while successfully de-targeting the liver and, importantly, the heart. Notably, both approaches outperformed conditionally self-silencing constructs that utilized artificial miRNAs (amiRs) driven by liver (LP1)- or heart (troponin T)-specific promoters. In summary, we expand the AAV toolbox by introducing expression cassette designs that enable specific expression in adipose tissue and skeletal muscle, thereby facilitating mechanistic studies in metabolic and muscle disease research. Strobel and colleagues applied two miRNA-based strategies to enhance AAV-mediated tissue-selective expression in mice. Both approaches—off-target-tissue-specific promoters driving self-silencing artificial miRNAs and the incorporation of endogenous miRNA target sites—achieved high adipose and skeletal muscle selectivity, thereby expanding the AAV toolbox for mechanistic studies.

Authors

Institutions

Publication Details

Journal
Molecular Therapy Advances
Published
2025-12-26
DOI
https://doi.org/10.1016/j.omta.2025.201664
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

MicroRNA-based targeting strategies enable AAV-mediated, tissue-selective gene expression in adipose tissue and skeletal muscle of mice

Simon Holdenried-Krafft, Charlotte Lempp, Benjamin Strobel, Gina Blahetek et al.
Molecular Therapy Advances
Virus-based gene therapy research
article

MicroRNA-based targeting strategies enable AAV-mediated, tissue-selective gene expression in adipose tissue and skeletal muscle of mice

Simon Holdenried-Krafft, Charlotte Lempp, Benjamin Strobel, Gina Blahetek, Sarah Abele, Damian Matera, Emilia Schmierer, Peter Gross, Tanja Schönberger, Anna Geisbauer
article en

Abstract

Functional validation of therapeutic concepts—including understanding a target protein’s mode of action in disease-relevant tissues—is a critical component of early drug discovery research. Tissue selectivity of recombinant adeno-associated viral vectors (AAVs) is an important property for both gene therapy and the modulation of target genes in model organisms, to investigate protein function and signaling pathways in specific cell types and tissues. However, while many target tissues can be transduced efficiently by selected capsids, achieving tissue specificity remains challenging in certain contexts. In this study, we compared different microRNA (miRNA)-based strategies to transcriptionally restrict AAV expression to either adipose tissue or skeletal muscle. Our findings demonstrate that liver-specific miR122 effectively suppressed AAV9-driven liver expression, while preserving adipose tissue targeting efficiency. Similarly, AAVMYO, in combination with a muscle-specific promoter and target sites for miR208a, confined transgene expression to skeletal muscle, while successfully de-targeting the liver and, importantly, the heart. Notably, both approaches outperformed conditionally self-silencing constructs that utilized artificial miRNAs (amiRs) driven by liver (LP1)- or heart (troponin T)-specific promoters. In summary, we expand the AAV toolbox by introducing expression cassette designs that enable specific expression in adipose tissue and skeletal muscle, thereby facilitating mechanistic studies in metabolic and muscle disease research. Strobel and colleagues applied two miRNA-based strategies to enhance AAV-mediated tissue-selective expression in mice. Both approaches—off-target-tissue-specific promoters driving self-silencing artificial miRNAs and the incorporation of endogenous miRNA target sites—achieved high adipose and skeletal muscle selectivity, thereby expanding the AAV toolbox for mechanistic studies.

Molecular Therapy AdvancesVol. 34(1)
Boehringer Ingelheim (Germany) (DE), Boehringer Ingelheim (France) (FR)
Openalex Percentile: Top 25%
Virus-based gene therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.